开放性眼外伤管理策略与交感性眼炎风险:一项Meta分析
该系统综述与Meta分析检索五个期刊数据库,纳入8项报告交感性眼炎(SO)结局的观察性研究,共7500例患者和7635处开放性眼外伤(OGI)。汇总后OGI后SO发生率为0.12%(95%CI 0.00%-0.25%),一期眼球摘除或眼内容剜出组为0.05%(95%CI 0.00%-0.21%),一期修复组为0.15%(95%CI 0.00%-0.33%)。作者结论认为基于现有数据,无证据表明一期眼球摘除或眼内容剜出可降低继发性SO风险。
要点
- OGI后汇总SO发生率为0.12%(95%CI 0.00%-0.25%)。
- 一期眼球摘除或眼内容剜出组SO汇总估计为0.05%(95%CI 0.00%-0.21%)。
- 一期修复组SO汇总估计为0.15%(95%CI 0.00%-0.33%)。
核心结论
- 基于现有数据,无证据表明一期眼球摘除或一期眼内容剜出可降低继发性交感性眼炎的风险。
研究设计与样本
- 系统综述与Meta分析,检索五个期刊数据库,检索日期为2021年6月29日,更新至2022年12月10日,注册号CRD42021262616。
- 纳入报告交感性眼炎结局的前瞻性或回顾性研究,共纳入8项研究、7500例患者和7635处开放性眼外伤。
- 采用随机效应模型估计汇总SO发生率和绝对风险降低(ARR),并按GRADE进行证据分级。
主要发现
- 7620处开放性眼外伤纳入分析,其中21例患者发生SO。
- 所有纳入研究汇总后,开放性眼外伤后SO估计发生率为0.12%(95%CI 0.00%-0.25%)。
- 779例接受一期眼球摘除或一期眼内容剜出的患者中未报告SO病例,汇总SO估计为0.05%(95%CI 0.00%-0.21%)。
- 一期修复组的SO汇总估计发生率为0.15%(95%CI 0.00%-0.33%)。
- 随机效应模型ARR为-0.0010(支持眼球摘除,95%CI -0.0031[支持眼球摘除]至0.0011[支持一期修复])。
关键数值与推荐
- GRADE分析因纳入研究为观察性研究及缺失数据导致的偏倚风险,判定证据确定性低。
- 原文报告ARR为-0.0010(支持眼球摘除,95%CI -0.0031至0.0011),置信区间跨0。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- GRADE分析强调证据确定性低,因为纳入研究为观察性研究。
- 缺失数据导致偏倚风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TOPIC: Sympathetic ophthalmia (SO) is a sight-threatening granulomatous panuveitis caused by a sensitizing event. Primary enucleation or primary evisceration, versus primary repair, as a risk management strategy after open-globe injury (OGI) remains controversial. CLINICAL RELEVANCE: This systematic review was conducted to report the incidence of SO after primary repair compared with that of after primary enucleation or primary evisceration. This enabled the reporting of an estimated number needed to treat. METHODS: Five journal databases were searched. This review was registered with International Prospective Register of Systematic Reviews (identifier, CRD42021262616). Searches were carried out on June 29, 2021, and were updated on December 10, 2022. Prospective or retrospective studies that reported outcomes (including SO or lack of SO) in a patient population who underwent either primary repair and primary enucleation or primary evisceration were included. A systematic review and meta-analysis were carried out in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Random effects modelling was used to estimate pooled SO rates and absolute risk reduction (ARR). RESULTS: Eight studies reporting SO as an outcome were included in total. The included studies contained 7500 patients and 7635 OGIs. In total, 7620 OGIs met the criteria for inclusion in this analysis; SO developed in 21 patients with OGI. When all included studies were pooled, the estimated SO rate was 0.12% (95% confidence interval [CI], 0.00%-0.25%) after OGI. Of 779 patients who underwent primary enucleation or primary evisceration, no SO cases were reported, resulting in a pooled SO estimate of 0.05% (95% CI, 0.00%-0.21%). For primary repair, the pooled estimate of SO rate was 0.15% (95% CI, 0.00%-0.33%). The ARR using a random effects model was -0.0010 (in favour of eye removal; 95% CI, -0.0031 [in favor of eye removal] to 0.0011 [in favor of primary repair]). Grading of Recommendations, Assessment, Development, and Evaluations analysis highlighted a low certainty of evidence because the included studies were observational, and a risk of bias resulted from missing data. DISCUSSION: Based on the available data, no evidence exists that primary enucleation or primary evisceration reduce the risk of secondary SO. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Patterson TJ, Kedzierski A, McKinney D, et al. The Risk of Sympathetic Ophthalmia Associated with Open-Globe Injury Management Strategies: A Meta-analysis. Ophthalmology. 2023. PMID: 38086434. doi:10.1016/j.ophtha.2023.12.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。